Bevacizumab, 2 mg

Bevacizumab belongs to a class of compounds with well-established chemical utility, characterized by the molecular formula C16H21NO3 and a molecular weight of 275.34. This compound is structurally related to monoclonal antibodies, a group of proteins known for their ability to recognize and bind specifically to antigens. As such, Bevacizumab exhibits selective binding properties towards vascular endothelial growth factor (VEGF), thereby inhibiting angiogenesis, a process essential for tumor growth. Due to its specific interaction with VEGF, it carries a Warning signal word, indicating potential harm if swallowed. Additionally, Bevacizumab has been approved for clinical use as an anti-cancer agent, particularly in combination therapies for various types of cancer.

• CAS Number: 216974-75-3
• Molecular Formula: C16H21NO3
• Exact Mass: 275.15214353
• GHS Signal Word: Warning
• Molecular Weight: 275.34
• Hazard Statements:
• H302: Harmful if swallowed [Warning Acute toxicity, oral]